Letter to the Editor Open Access
Immune Checkpoint Inhibitor Duration in Advanced Solid Tumors: Should Treatment Stop at Two Years?
Suleyman Can1,*
- 1Department of Medical Oncology, Siirt Training and Research Hospital, Siirt, Turkey
Corresponding Author
Suleyman Can, suleycan@gmail.com
Received Date: August 03, 2026
Accepted Date: October 14, 2026
Can S. Immune Checkpoint Inhibitor Duration in Advanced Solid Tumors: Should Treatment Stop at Two Years? J Cancer Immunol. 2026;8(3):121–123.
Copyright: © 2026 Can S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Prevalence of Symptom Clusters in Cancer Patients at First Presentation in Palliative Care Clinic as per Different Disease Groups
Cancer has its own disease burden and patients usually suffer from symptom clusters when they are referred for palliative treatment. Identification of symptom cluster trajectories will help clinician to take into account measures that can optimize quality of life of palliative patients. Therefore the aim of this paper is to determine the overall prevalence of symptoms and symptoms clusters in different disease groups according to etiology at the time of first visit to Palliative care clinic by using HIS Palliative First Assessment note indicating Edmonton symptom scale.
Chimeric Antigen Receptor CAR NK Cells Emerging Immunotherapy for the Treatment of Cancer
Although NK cells are recognized as effector lymphocytes of the innate immune system, they also regulate the adaptive immune response by releasing inflammatory cytokines and developing immunological memory. Unlike other lymphocytes such as T or B cells, NK cells do not express rearrangeable, antigen-specific receptors.
Emerging Role of TRPML1 Mucolipin Endolysosomal Channel in Cancer
The transient receptor potential mucolipin 1 (TRPML1) is an endolysosomal channel belonging to the TRP family. Clinically, mutations of TRPML1 have been responsible for a severe lysosomal storage disorder called mucolipidosis type IV.
Uniportal VATS Lobectomy for Lung Cancer: Feasibility and Cost Effectiveness in a Single Center Experience
In last decades, video-assisted thoracic surgery (VATS) together with robotic-assisted thoracic surgery (RATS) can be considered the biggest innovation in thoracic surgery. This approach drastically changed the way of performing surgical operations, improving patient’s outcome undergoing thoracic surgery.
Circulating Cell-Free RNA: A New Perspective for Endometrial Cancer
In order to implement the knowledge of cancer to monitor its evolution and setting, in the last decade, new minimally invasive and repeatable samples collection have been developed such as liquid biopsy. Cancer biomarkers originating from tumors can represent the molecular status of the tumor or its metastases which release them directly into body fluids or indirectly due to disruption of tumor/metastatic tissue. These biomarkers are detectable in liquid biopsy.